U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. News & Events
  3. FDA Meetings, Conferences and Workshops
  4. OCE Conversations on Cancer, Cervical Cancer Treatment Innovation: A Collaborative Discussion - 01/14/2025
  1. FDA Meetings, Conferences and Workshops

Webcast | Virtual

Event Title
OCE Conversations on Cancer, Cervical Cancer Treatment Innovation: A Collaborative Discussion
January 14, 2025

Date:
January 14, 2025
Time:
10:00 a.m. - 11:00 a.m. ET
Organized By:
Organizer
Image
OCE Conversations on Cancer, Cervical Cancer Treatment Innovation: A Collaborative Discussion

Twitter: #ConversationsOnCancer
Sponsored by the U.S. Food & Drug Administration (FDA)

Background:

The FDA Oncology of Excellence (OCE) in collaboration with the European Medicines Agency (EMA) presents a Conversations on Cancer program, January 14, 2025, 10:00-11:00 AM ET/16:00-17:00 PM CET. The session, titled Cervical Cancer Treatment Innovation: A Collaborative Discussion, will commemorate Cervical Cancer Awareness Month. 

Even though cervical cancer is the fourth most common cancer in women globally and is the most common cancer related cause of death in some regions, historically there was minimal drug development for metastatic and recurrent disease. In the US and Europe, while the earliest approvals to treat cervical cancer were granted in the 1970s, there was limited further drug development until the last decade. Since then, an acceleration of drug development has brought anti-PD1 directed therapy and targeted therapies to patients. The year 2024 was a banner year and ongoing investigation into innovative therapeutic approaches means there is much for patients to remain hopeful about on the horizon. 

Join us for an engaging discussion that will bring Join us for an engaging discussion that will bring together key stakeholders in the fight against cervical cancer, including representatives from the patient advocacy community, academia, community oncology, the EMA and the FDA to discuss the historical path that has led us to the current treatment landscape, the impact of new therapies on individuals with cervical cancer and their families, areas of ongoing high impact research, and what the future might bring.

Discussion topics will include: 

  1. Raising awareness of cervical cancer  
  2. Historical development of cervical cancer therapy 
  3. Impact of new therapies on patients, their families, and friends 
  4. Ongoing clinical trials  
  5. Opportunities to drive further improvement in outcomes for individuals with cervical cancer 

Webcast Information: 

A free-of-charge webcast of this public panel discussion will be provided. Registration for the webcast is required at the link above.

FDA plans to post archived webcast of this Conversations on Cancer program at: https://www.fda.gov/about-fda/project-community/conversations-cancer

Contact:

For any inquiries regarding this program, please send an email to: OCE-Engagement@fda.hhs.gov

Back to Top